Study Summary
Efficacy study about donor derived CD19-target T cell to treat B-ALL post hematopoietic stem cell transplantation
Want to learn more about this trial?
Request More InfoInterventions
IM19 CAR-TBIOLOGICAL
All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Peking University people's hospita | Beijing | Beijing Municipality | China |